Even with attaining an entire reaction with optimal induction therapy, minimum residual disease frequently persists, necessitating consolidation therapy to mitigate the risk of relapse by reducing residual illness. In sufferers which have gained seven+3 induction therapy, consolidation therapy is initiated with high-dose cytarabine, also referred